Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Arcus Biosciences ( (RCUS) ) has issued an update.
On December 18, 2025, Arcus Biosciences amended its existing loan and security agreement with a syndicate of lenders led by Hercules Capital, restructuring access to the remaining $150 million term loan facility into four tranches tied to specific time windows and clinical and regulatory milestones, and extending the facility’s maturity date to September 1, 2030. The amendment introduces new performance covenants that apply if outstanding borrowings exceed $200 million, requiring Arcus, after achieving an FDA approval milestone, to maintain either a minimum market capitalization with sufficient qualified cash, higher levels of qualified cash alone, or to meet defined net product revenue thresholds, effectively tightening financial discipline as the company advances its late-stage programs and approaches potential commercialization.
The most recent analyst rating on (RCUS) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Arcus Biosciences stock, see the RCUS Stock Forecast page.
Spark’s Take on RCUS Stock
According to Spark, TipRanks’ AI Analyst, RCUS is a Neutral.
Arcus Biosciences’ overall stock score reflects significant financial challenges and a negative valuation, offset by positive technical indicators and promising corporate developments. The company’s ability to navigate financial difficulties and capitalize on promising study results will be crucial for future performance.
To see Spark’s full report on RCUS stock, click here.
More about Arcus Biosciences
Arcus Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing innovative drug candidates, including biologics and small molecules, with a strategy centered on advancing therapies through late-stage clinical trials toward potential U.S. Food and Drug Administration approvals.
Average Trading Volume: 1,781,577
Technical Sentiment Signal: Buy
Current Market Cap: $2.75B
For detailed information about RCUS stock, go to TipRanks’ Stock Analysis page.